Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jan 18;82(2):368–373. doi: 10.1054/bjoc.1999.0928

Number of apoptotic cells as a prognostic marker in invasive breast cancer

J S de Jong 1, P J van Diest 1, J P A Baak 1
PMCID: PMC2363300  PMID: 10646890

Abstract

Apoptosis plays an important role in tumorigenesis. Tumour growth is determined by the rate of cell proliferation and cell death. We counted the number of apoptotic cells in haematoxylin and eosin (H&E)-stained tumour sections in series of 172 grade I and II invasive breast cancers with long-term follow-up. The number of apoptotic cells in ten high-power fields were converted to the number of apoptotic cells per mm2to obtain the apoptotic index (AI). The AI showed a positive correlation to the mitotic activity index (MAI) (P = 0.0001), histological grade (P< 0.0001) and worse tumour differentiation. Patients with high AI showed shorter overall survival than patients with low AI in the total group as well as in the lymph node-positive group. Tumour size, MAI, lymph node status and AI were independent prognostic indicators in multivariate analysis. The AI was shown to be of additional prognostic value to the MAI in the total patients group as well as in the lymph node-positive group. The correlation between the AI and the MAI points to linked mechanisms of apoptosis and proliferation. Since apoptotic cells can be counted with good reproducibility in H&E-stained tumour sections, the AI may be used as an additional prognostic indicator in invasive breast cancer. © 2000 Cancer Research Campaign

Keywords: breast cancer, apoptosis, proliferation, prognostic factor

Full Text

The Full Text of this article is available as a PDF (201.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baak J. P., Van Dop H., Kurver P. H., Hermans J. The value of morphometry to classic prognosticators in breast cancer. Cancer. 1985 Jul 15;56(2):374–382. doi: 10.1002/1097-0142(19850715)56:2<374::aid-cncr2820560229>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  2. Barbareschi M., Caffo O., Veronese S., Leek R. D., Fina P., Fox S., Bonzanini M., Girlando S., Morelli L., Eccher C. Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. Hum Pathol. 1996 Nov;27(11):1149–1155. doi: 10.1016/s0046-8177(96)90307-x. [DOI] [PubMed] [Google Scholar]
  3. Bargou R. C., Daniel P. T., Mapara M. Y., Bommert K., Wagener C., Kallinich B., Royer H. D., Dörken B. Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer. 1995 Mar 16;60(6):854–859. doi: 10.1002/ijc.2910600622. [DOI] [PubMed] [Google Scholar]
  4. Berardo M. D., Elledge R. M., de Moor C., Clark G. M., Osborne C. K., Allred D. C. bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer. 1998 Apr 1;82(7):1296–1302. [PubMed] [Google Scholar]
  5. Berns E. M., Klijn J. G., van Putten W. L., van Staveren I. L., Portengen H., Foekens J. A. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res. 1992 Mar 1;52(5):1107–1113. [PubMed] [Google Scholar]
  6. Borg A., Baldetorp B., Fernö M., Olsson H., Sigurdsson H. c-myc amplification is an independent prognostic factor in postmenopausal breast cancer. Int J Cancer. 1992 Jul 9;51(5):687–691. doi: 10.1002/ijc.2910510504. [DOI] [PubMed] [Google Scholar]
  7. Clayton F. Pathologic correlates of survival in 378 lymph node-negative infiltrating ductal breast carcinomas. Mitotic count is the best single predictor. Cancer. 1991 Sep 15;68(6):1309–1317. doi: 10.1002/1097-0142(19910915)68:6<1309::aid-cncr2820680621>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  8. Davis P. L., Shaiu W. L., Scott G. L., Iglehart J. D., Hsieh T. S., Marks J. R. Complex response of breast epithelial cell lines to topoisomerase inhibitors. Anticancer Res. 1998 Jul-Aug;18(4C):2919–2932. [PubMed] [Google Scholar]
  9. Doglioni C., Dei Tos A. P., Laurino L., Chiarelli C., Barbareschi M., Viale G. The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. Virchows Arch. 1994;424(1):47–51. doi: 10.1007/BF00197392. [DOI] [PubMed] [Google Scholar]
  10. Evan G. I., Wyllie A. H., Gilbert C. S., Littlewood T. D., Land H., Brooks M., Waters C. M., Penn L. Z., Hancock D. C. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 1992 Apr 3;69(1):119–128. doi: 10.1016/0092-8674(92)90123-t. [DOI] [PubMed] [Google Scholar]
  11. Farrow S. N., Brown R. New members of the Bcl-2 family and their protein partners. Curr Opin Genet Dev. 1996 Feb;6(1):45–49. doi: 10.1016/s0959-437x(96)90009-x. [DOI] [PubMed] [Google Scholar]
  12. Gulli L. F., Palmer K. C., Chen Y. Q., Reddy K. B. Epidermal growth factor-induced apoptosis in A431 cells can be reversed by reducing the tyrosine kinase activity. Cell Growth Differ. 1996 Feb;7(2):173–178. [PubMed] [Google Scholar]
  13. Heatley M. K. Association between the apoptotic index and established prognostic parameters in endometrial adenocarcinoma. Histopathology. 1995 Nov;27(5):469–472. doi: 10.1111/j.1365-2559.1995.tb00312.x. [DOI] [PubMed] [Google Scholar]
  14. Hollowood K., Macartney J. C. Reduced apoptotic cell death in follicular lymphoma. J Pathol. 1991 Apr;163(4):337–342. doi: 10.1002/path.1711630411. [DOI] [PubMed] [Google Scholar]
  15. Jannink I., van Diest P. J., Baak J. P. Comparison of the prognostic value of four methods to assess mitotic activity in 186 invasive breast cancer patients: classical and random mitotic activity assessments with correction for volume percentage of epithelium. Hum Pathol. 1995 Oct;26(10):1086–1092. doi: 10.1016/0046-8177(95)90270-8. [DOI] [PubMed] [Google Scholar]
  16. Kapucuoglu N., Losi L., Eusebi V. Immunohistochemical localization of Bcl-2 and Bax proteins in in situ and invasive duct breast carcinomas. Virchows Arch. 1997 Jan;430(1):17–22. doi: 10.1007/BF01008011. [DOI] [PubMed] [Google Scholar]
  17. Krajewski S., Blomqvist C., Franssila K., Krajewska M., Wasenius V. M., Niskanen E., Nordling S., Reed J. C. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 1995 Oct 1;55(19):4471–4478. [PubMed] [Google Scholar]
  18. Krajewski S., Krajewska M., Shabaik A., Miyashita T., Wang H. G., Reed J. C. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol. 1994 Dec;145(6):1323–1336. [PMC free article] [PubMed] [Google Scholar]
  19. Kranenburg O., van der Eb A. J., Zantema A. Cyclin D1 is an essential mediator of apoptotic neuronal cell death. EMBO J. 1996 Jan 2;15(1):46–54. [PMC free article] [PubMed] [Google Scholar]
  20. Leoncini L., Del Vecchio M. T., Megha T., Barbini P., Galieni P., Pileri S., Sabattini E., Gherlinzoni F., Tosi P., Kraft R. Correlations between apoptotic and proliferative indices in malignant non-Hodgkin's lymphomas. Am J Pathol. 1993 Mar;142(3):755–763. [PMC free article] [PubMed] [Google Scholar]
  21. Lipponen P. K., Aaltomaa S. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J Pathol. 1994 Aug;173(4):333–339. doi: 10.1002/path.1711730408. [DOI] [PubMed] [Google Scholar]
  22. Lipponen P. K., Collan Y., Eskelinen M. J. Volume corrected mitotic index (M/V index), mitotic activity index (MAI), and histological grading in breast cancer. Int Surg. 1991 Oct-Dec;76(4):245–249. [PubMed] [Google Scholar]
  23. Lipponen P., Aaltomaa S., Kosma V. M., Syrjänen K. Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer. 1994;30A(14):2068–2073. doi: 10.1016/0959-8049(94)00342-3. [DOI] [PubMed] [Google Scholar]
  24. Lipponen P. Apoptosis in breast cancer: relationship with other pathological parameters. Endocr Relat Cancer. 1999 Mar;6(1):13–16. doi: 10.1677/erc.0.0060013. [DOI] [PubMed] [Google Scholar]
  25. Minn A. J., Boise L. H., Thompson C. B. Bcl-x(S) anatagonizes the protective effects of Bcl-x(L). J Biol Chem. 1996 Mar 15;271(11):6306–6312. doi: 10.1074/jbc.271.11.6306. [DOI] [PubMed] [Google Scholar]
  26. Miyashita T., Kitada S., Krajewski S., Horne W. A., Delia D., Reed J. C. Overexpression of the Bcl-2 protein increases the half-life of p21Bax. J Biol Chem. 1995 Nov 3;270(44):26049–26052. doi: 10.1074/jbc.270.44.26049. [DOI] [PubMed] [Google Scholar]
  27. Mustonen M., Raunio H., Päkkö P., Soini Y. The extent of apoptosis is inversely associated with bcl-2 expression in premalignant and malignant breast lesions. Histopathology. 1997 Oct;31(4):347–354. doi: 10.1046/j.1365-2559.1997.2710877.x. [DOI] [PubMed] [Google Scholar]
  28. Perego P., Giarola M., Righetti S. C., Supino R., Caserini C., Delia D., Pierotti M. A., Miyashita T., Reed J. C., Zunino F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res. 1996 Feb 1;56(3):556–562. [PubMed] [Google Scholar]
  29. Sierra A., Castellsagué X., Coll T., Mañas S., Escobedo A., Moreno A., Fabra A. Expression of death-related genes and their relationship to loss of apoptosis in T1 ductal breast carcinomas. Int J Cancer. 1998 Apr 17;79(2):103–110. doi: 10.1002/(sici)1097-0215(19980417)79:2<103::aid-ijc1>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  30. Sjöström J., Krajewski S., Franssila K., Niskanen E., Wasenius V. M., Nordling S., Reed J. C., Blomqvist C. A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer. Br J Cancer. 1998 Sep;78(6):812–815. doi: 10.1038/bjc.1998.584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Staunton M. J., Gaffney E. F. Apoptosis: basic concepts and potential significance in human cancer. Arch Pathol Lab Med. 1998 Apr;122(4):310–319. [PubMed] [Google Scholar]
  32. Uyterlinde A. M., Schipper N. W., Baak J. P., Peterse H., Matze E. Limited prognostic value of cellular DNA content to classical and morphometrical parameters in invasive ductal breast cancer. Am J Clin Pathol. 1988 Mar;89(3):301–307. doi: 10.1093/ajcp/89.3.301. [DOI] [PubMed] [Google Scholar]
  33. Veronese S., Mauri F. A., Caffo O., Scaioli M., Aldovini D., Perrone G., Galligioni E., Doglioni C., Dalla Palma P., Barbareschi M. Bax immunohistochemical expression in breast carcinoma: a study with long term follow-up. Int J Cancer. 1998 Feb 20;79(1):13–18. doi: 10.1002/(sici)1097-0215(19980220)79:1<13::aid-ijc3>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  34. Wijsman J. H., Jonker R. R., Keijzer R., van de Velde C. J., Cornelisse C. J., van Dierendonck J. H. A new method to detect apoptosis in paraffin sections: in situ end-labeling of fragmented DNA. J Histochem Cytochem. 1993 Jan;41(1):7–12. doi: 10.1177/41.1.7678025. [DOI] [PubMed] [Google Scholar]
  35. Yang E., Korsmeyer S. J. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood. 1996 Jul 15;88(2):386–401. [PubMed] [Google Scholar]
  36. Zhang G. J., Kimijima I., Abe R., Watanabe T., Kanno M., Hara K., Tsuchiya A. Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers. Anticancer Res. 1998 May-Jun;18(3B):1989–1998. [PubMed] [Google Scholar]
  37. de Jong J. S., van Diest P. J., Michalides R. J., van der Valk P., Meijer C. J., Baak J. P. Correlation of cyclin D1 and Rb gene expression with apoptosis in invasive breast cancer. Mol Pathol. 1998 Feb;51(1):30–34. doi: 10.1136/mp.51.1.30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. van Diest P. J., Michalides R. J., Jannink L., van der Valk P., Peterse H. L., de Jong J. S., Meijer C. J., Baak J. P. Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. Am J Pathol. 1997 Feb;150(2):705–711. [PMC free article] [PubMed] [Google Scholar]
  39. van Slooten H. J., van de Vijver M. J., van de Velde C. J., van Dierendonck J. H. Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity. Br J Cancer. 1998 Mar;77(5):789–796. doi: 10.1038/bjc.1998.128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. van de Schepop H. A., de Jong J. S., van Diest P. J., Baak J. P. Counting of apoptotic cells: a methodological study in invasive breast cancer. Clin Mol Pathol. 1996 Aug;49(4):M214–M217. doi: 10.1136/mp.49.4.m214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. van der Linden J. C., Baak J. P., Lindeman J., Hermans J., Meyer C. J. Prospective evaluation of prognostic value of morphometry in patients with primary breast cancer. J Clin Pathol. 1987 Mar;40(3):302–306. doi: 10.1136/jcp.40.3.302. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES